| Literature DB >> 27646737 |
Marcia S Driscoll1, Kathryn Martires2, Amy Kalowitz Bieber2, Miriam Keltz Pomeranz2, Jane M Grant-Kels3, Jennifer A Stein4.
Abstract
Malignant melanoma is the most common malignancy during pregnancy, and is diagnosed during childbearing age in approximately one-third of women diagnosed with melanoma. The impact of hormonal changes during pregnancy and from iatrogenic hormones on melanoma is controversial. Women undergo immunologic changes during pregnancy that may decrease tumor surveillance. In addition, hormone receptors are found on some melanomas. In spite of these observations, the preponderance of evidence does not support a poorer prognosis for pregnancy-associated melanomas. There is also a lack of evidence that oral contraceptives or hormone replacement therapy worsens melanoma prognosis.Entities:
Keywords: hormone replacement therapy; melanoma; oral contraceptives; pregnancy; prognosis; review
Mesh:
Year: 2016 PMID: 27646737 DOI: 10.1016/j.jaad.2016.01.061
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 11.527